ISPOR - HTA18 First to Launch, First to Falter? An Investigation Into the Clinical Benefits and HTA Outcomes for First-in-Class Drugs

Full Text

HTA18 First to Launch, First to Falter? An Investigation Into the Clinical Benefits and HTA Outcomes for First-in-Class Drugs

Abstract

Authors

D Civitelli K Politopoulou M Mills P Kanavos

Back to Volume 27, Supplemental Issue 12S

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now